Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24;184(7):437.
doi: 10.1007/s00431-025-06275-6.

RSV bronchiolitis: a disease only for those who do not receive prophylaxis

A Villani  1   2 , L Antilici  3 , A M C Musolino  1 , A Merola  1 , C F Perno  4 , M Raponi  5 , A C Vittucci  1
Affiliations

RSV bronchiolitis: a disease only for those who do not receive prophylaxis

A Villani et al. Eur J Pediatr. .

Abstract

Bronchiolitis is a leading cause of hospitalization in infants, with RSV being the primary pathogen. In 2023, nirsevimab was approved for universal prophylaxis, demonstrating high effectiveness in reducing RSV-related hospitalizations. In Italy, nirsevimab was introduced in the vaccination schedule only during the current 2024-2025 epidemic season, with significant regional differences. In our region, Lazio, nirsevimab was introduced in late November 2024, leading only to a 43% overall reduction in RSV bronchiolitis hospitalizations compared to the previous season. The highest impact was observed in newborns immunized at birth (- 82.7%), while the catch-up group showed lower-than-expected benefits (- 29%). Immunized infants had significantly lower oxygen requirements (42.9% vs. 82.4% in non-immunized) and resulted to be approximately seven times more likely not to require oxygen compared to non-immunized patients.

Conclusion: Universal infant immunization against RSV marks a significant breakthrough in the natural history of bronchiolitis, and early and widespread nirsevimab administration appears to be crucial in minimizing RSV's hospitalizations.

What is known: • Nirsevimab was approved in 2023 for the universal prophylaxis against RSV bronchiolitis. • Nirsevimab was was introduced in the Italian vaccination schedule only during the current 2024-2025 epidemic season, with significant regional differences.

What is new: • In Lazio, Italy, the delayed introduction of nirsevimab in November 2024 and the reduced vaccination coverage of the catch-up group resulted in a lower-than-expected reduction in RSV bronchiolitis hospitalizations. • Early and widespread administration of nirsevimab is crucial to maximizing its benefits and reducing severe RSV cases.

Keywords: Bronchiolitis; Immunization; Nirsevimab; RSV.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: The study was approved by the Ethics Committee of the Bambino Gesù Children’s Hospital (protocol 3460/2024 OPBG). The study was performed in line with the principles of the Declaration of Helsinki and its later amendments or comparable ethical standards. Competing interests: The authors declare no competing interests.

References

    1. Li Y et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399(10340):2047–2064. https://doi.org/10.1016/S0140-6736(22)00478-0 - DOI - PubMed - PMC
    1. De Luca D, Sanchez-Luna M, Schettler K, Bont L, Baraldi E (2023) Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt. Lancet Reg Health - Europe 34:100753. https://doi.org/10.1016/j.lanepe.2023.100753 - DOI - PubMed
    1. Ares-Gómez S et al (2024) Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis 24(8):817–828. https://doi.org/10.1016/S1473-3099(24)00215-9 - DOI - PubMed
    1. (2025) The Lancet Regional Health – Europe, “The Italian health data system is broken,” Elsevier Ltd. https://doi.org/10.1016/j.lanepe.2024.101206 .
    1. https://www.wikivaccini.regione.lombardia.it/wps/portal/site/wikivaccini... , “Campagna di immunizzazione anti-RSV.” Accessed 19 June 2025

MeSH terms

Substances

LinkOut - more resources